


CLAIMS


1. A compound represented by Formula 1:

[Formula 1]




;

wherein:



R^2 is selected from hydrogen, substituted or unsubstituted C_{1-6} alkyl, and  ;

R^3 is selected from substituted or unsubstituted C_{1-6} alkyl, , and  ;

R^4 and R^5 are each independently hydrogen, substituted or unsubstituted C_{1-6} alkyl, $-OR_b$, $-CH_2OR_b$, or -halogen,

provided that at least one of R^4 or R^5 is not H;

R_b is hydrogen or C_{1-6} alkyl;

R_a is hydrogen or C_{1-6} alkyl;

n is an integer from 1 to 10;

wherein R^6 to R^9 are each independently hydrogen or substituted or unsubstituted C_{1-6} alkyl, and the substituent is $-C(=O)NH_2$;


further wherein, unless otherwise specified, when a group is substituted, it is

substituted with a substituent selected from $-X_1$, $-R_j$, $-O^-$, $=O$, $-OR_j$, $-SR_j$, $-S^-$, $-N(R_j)_2$, $-N^+(R_j)_3$, $=NR_j$, $-C(X_1)_3$, $-CN$, $-OCN$, $-SCN$, $-N=C=O$, $-NCS$, $-NO$, $-NO_2$, $=N-OH$, $=N_2$, $-N_3$, $-NHC(=O)R_j$, $-C(=O)R_j$, $-C(=O)NR_jR_j$, $-S(=O)_2O^-$, $-S(=O)_2OH$, $-S(=O)_2R_j$, $-OS(=O)_2OR_j$, $-S(=O)_2NR_j$, $-S(=O)R_j$, $-OP(=O)(OR_j)_2$, $-C(=O)R_j$, alkylene- $C(=O)R_j$, $-C(=S)R_j$, $-C(=O)OR_j$, alkylene- $C(=O)OR_j$, $-C(=O)O^-$, alkylene- $C(=O)O^-$, $-C(=S)OR_j$, $-C(=O)SR_j$, $-C(=S)SR_j$, $-C(=O)NR_jR_j$, alkylene- $C(=O)NR_jR_j$, $-C(=S)NR_jR_j$, and $-C(-NR_j)NR_jR_j$;


X_1 is F, Cl, Br, or I;

each occurrence of R_j is independently hydrogen, C_{1-6} alkyl, C_{5-12} aryl, C_{7-12} arylalkyl, or heterocycle; and



further wherein the compound is not HyP-Gly-Gln-Asp-Gly-Leu-Ala-Gly-Pro-Lys.



3. The compound of claim 1, wherein R^2 is selected from , ,



4. The compound of claim 1, wherein R^3 is selected from



5. The compound of claim 1, wherein R^4 is selected from the group consisting of H, -OH, and -CH₃.

6. A compound selected from the group consisting of HyP-Gly-Gln-Glu-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Asn-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Gln-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-His-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Lys-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Ser-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Thr-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Ala-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Val-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Ile-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Phe-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Tyr-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Trp-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Ser(Homo)-Gly-Leu-Ala-Gly-Pro-Lys, D -HyP(2R, 4S)-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, D -Hyp(2R,4S)-Gly- D -Gln- D -Leu-Gly- D -Leu- D -Ala-Gly- D -Pro- D -Lys, D -Hyp(2R, 4R)-Gly- D -Gln- D -Leu-Gly- D -Leu- D -Ala-Gly- D -Pro- D -Lys,

HyP-Gly-Gln-Asp-Val-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Asp-Ile-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Asp-Leu-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Asp-Ala-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Asp-Ser-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Asp-Thr-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Leu-Ala-Leu-Ala-Gly-Pro-Lys,

HyP-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Leu, HyP-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Glu, HyP-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Ala, _D-HyP(2R, 4S)-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Ala,

Hyp(2S, 4S)-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, (4-hydroxyMe)Pro-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, (4-Fluoro)Pro-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, (4-Dimethyl)Pro-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, (4-Me)Pro-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, (5-Me)Pro-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys,

Hyp-Gly-Ala-Leu-Gly-Leu-Ala-Gly-Pro-Lys, Hyp-Gly-Gln-Leu-Gly-Ala-Ala-Gly-Pro-Lys, Hyp-Gly-Gln-Leu-Gly-Leu-Ala-Ala-Pro-Lys, Hyp-Ala-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, _D-Hyp(2R, 4S)-Ala-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, and _D-Hyp(2R, 4S)-Ala-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Ala.


7. A peptide having an amino acid sequence represented by HyP-Gly-Gln-Xaa-Gly-Leu-Ala-Gly-Pro-Lys, wherein Xaa is selected from the group consisting of Glu, Asn, Gln, His, Lys, Ser, Thr, Ala, Val, Leu, Phe, Tyr, Trp, and homo-Ser.

8. A peptide having an amino acid sequence represented by HyP-Gly-Gln-Asp-Xaa-Leu-Ala-Gly-Pro-Lys, wherein Xaa is selected from the group consisting of Val, Ile, Leu, Ala, Ser, and Thr.


9. A peptide having an amino acid sequence represented by HyP-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Xaa, wherein Xaa is selected from the group consisting of Leu, Glu, and Ala.

10. A peptide having an amino acid sequence represented by PD-Gly-Gln-

Leu-Gly-Leu-Ala-Gly-Pro-Lys, wherein PD is any one selected from the group consisting of the following formulae:




11. A peptide having an amino acid sequence represented by PD-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, wherein PD is any one selected from the group consisting of the following formulae:



12. A peptide having any one amino acid sequence selected from the group consisting of Hyp-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Ala-Lys, Hyp-Gly-Gln-Glu-Gly-Lys-Gly, HyP-Gly-Gln-Leu-Gly-Leu, D -HyP(2R, 4S)-Gly- D -Gln- D -Leu-Gly- D -Leu, HyP-Gly-Gln-Leu-Gly, HyP-Gly-Gln- D -Leu-Gly, and D -HyP(2R, 4S)-Gly-Gln-Leu-Gly.


13. A compound represented by Formula 8:

[Formula 8]



14. A compound represented by Formula 10:

[Formula 10]



15. A pharmaceutical composition for use in the treatment of an eye disease, which comprises the compound according to any one of claims 1 to 6, 13, and 14, or the peptide according to any one of claims 7 to 12, as an active pharmaceutical ingredient.

16. Use of the compound according to any one of claims 1 to 6, 13, and 14, or the peptide according to any one of claims 7 to 12 in the manufacture of a pharmaceutical composition for treating an eye disease.

17. The use of claim 16, wherein the eye disease is one selected from the group consisting of retinopathy, keratitis, dry-macular degeneration, wet-macular degeneration, dry eye syndrome, heratoconjunctivitis sicca and keratoconjunctival epithelium disorder.